HUTCHMED (00013.HK): Sovleplenib Granted FDA Orphan Drug Designation for the Treatment of Primary Immune Thrombocytopenia

Zhitong Finance APP News, HUTCHMED (00013.HK) announced that sovleplenib has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary immune thrombocytopenia. Immune thrombocytopenia is an autoimmune disease that increases the risk of bleeding. Sovleplenib is a novel, highly selective oral spleen tyrosine kinase (Syk) inhibitor.